Treatment of Antibody-Mediated Renal Allograft Rejection: Improving Step by Step
Table 3
Main adverse events during the first year after treatment.
Group RLP ()
Group BLP ()
Group BHP ()
Haemoglobin reduction: baseline – nadir (mg/dL)
2.1 ± 1.5
2.3 ± 1.8
2.8 ± 1.3
n.s.
Thrombocytopenia (patients)
9
10
7
n.s.
Leukopenia (patients)
8
6
6
n.s.
Increase of serum transaminase levels (patients)
6
5
3
n.s.
Infections (events/patients)
14/7
12/7
9/2
n.s./n.s.
Urinary tract infection
7/4
2/1
7/1
n.s./n.s.
Otitis media
2/2
0/0
0/0
n.s./n.s.
Tonsillitis
0/0
1/1
1/1
n.s./n.s.
Pneumonia
1/1
0/0
0/0
n.s./n.s.
Enterocolitis
4/4
4/4
0/0
n.s./n.s.
Central venous catheter infection
0/0
2/2
0/0
n.s./n.s.
CMV reactivation
0/0
2/2
1/1
n.s./n.s.
Fever of unknown origin
0/0
1/1
0/0
n.s./n.s.
Nausea (patients)
0
0
2
n.s.
Vomiting (patients)
0
0
2
n.s.
Diarrhea (patients)
1
2
7
0.009 (RLP versus BHP)
Peripheral sensory neuropathy (patients)
0
0
2
n.s.
Allergic reaction to IVIG (patients)
1
1
1
n.s.
Hospitalizations (events/patients)
16/8
9/7
10/5
n.s./n.s.
Nonmelanoma skin cancer (patients)
0
0
2
n.s.
Adverse events during the first year after treatment are shown except for malignancies, where the whole follow-up period was considered. Note. Some patients suffered from more than one gastrointestinal adverse event (nausea, vomiting, or diarrhea) simultaneously. Group RLP, rituximab + low-dose IVIG + plasmapheresis; group BLP, bortezomib + low-dose IVIG + plasmapheresis; group BHP, bortezomib + high-dose IVIG + plasmapheresis.
